Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Budigalimab and/or ABBV-382 in People Living with HIV Undergoing Analytical Treatment Interruption
jRCT2051230193Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of budigalimab and ABBV-382 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Viral control without ART restart at Week 24. Started Mar 2024; status: active, not recruiting.
02
Drugs
budigalimabABBV-382
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT2051230193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230193.